Newsfile Corp
07 Aug 2026, 18:42 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA stated that the benefit-risk profile for Capricor's lead product candidate, Deramiocel, looked unfavorable due to a lack of evidence supporting its effectiveness. — A negative FDA assessment of a company's primary product candidate is typically a catalyst for significant stock price devaluation.
-0.90The FDA considers Capricor's statistical analyses for Deramiocel to be post-hoc and exploratory because the company changed its statistical analysis plan without FDA agreement. — Regulatory rejection of a study's methodology undermines the validity of the clinical data and increases the likelihood of a BLA rejection.
-0.70A class action securities lawsuit has been filed against Capricor and its executives for allegedly failing to disclose material information between December 17, 2025, and July 26, 2026. — Securities litigation creates legal liabilities and signals potential corporate governance or transparency issues to investors.
-0.40Continue reading
6 related stories
Top 3 movers · tap to explore
Which stocks this story touches
The company is facing a securities class action lawsuit following FDA briefing documents that questioned the accuracy of its data analysis and described the benefit-risk profile of its lead product as unfavorable.
The company is facing a securities class action following undisclosed growth obstacles and an approximately 70% decline in stock price.
The company is mentioned as the subject of a securities fraud class action related to alleged anticompetitive agreements and regulatory risks.
The company is mentioned in the context of a class action lawsuit application deadline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
48m ago
